Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

smacsJHI Dec. 6 at 11:57 PM

$ABEO Have they mentioned a plan for possible EU expansion of ROW?

1 · Reply

commoncentsinvestor Dec. 6 at 8:22 PM

$ABEO This is probably the most comprehensive evaluation of ABEO's potential available and shoud be required reading for every ABEO investor and those considering an investment in ABEO: Riverwater Partners Applying Our Three-Pillar Investment Framework to an Emerging Gene Therapy Leader (October 15, 2025). By Nathan Fredrick and Devaj Mehta. https://riverwaterpartners.com/2025/10/13/deep-dive-abeona/

0 · Reply

commoncentsinvestor Dec. 6 at 8:03 PM

$ABEO Franca_ole @Franca_ole· 10h "In the US, Zevaskyn costs $3.1 million per treatment according to the list price. I increased my position in $ABEO yesterday. Demand for Zevaskyn continues to grow. The company announced that it has now received Zevaskyn product order forms (ZPOFs) for 12 patients and each of them is currently in the process of scheduling treatments. In addition, the company has identified approximately 30 eligible patients at QTCs. Abeona continues to guide for the ability to treat up to 10 patients per month by mid-2026."

0 · Reply

FitzCatalyst Dec. 5 at 12:47 PM

$ABEO

0 · Reply

Lttiller Dec. 4 at 9:00 PM

$ABEO next major news coming out soon?

3 · Reply

PPT_for_me Dec. 4 at 7:16 PM

$ABEO Imagine shorting a company creating a cure for children with a horribly gruesome skin disease... disgusting.

3 · Reply

Playfire Dec. 4 at 4:52 PM

$ABEO That's right, Abeona has an unbelievable short interest rate and is still rising, let the cap fly!

1 · Reply

acm20 Dec. 4 at 4:46 PM

$ABEO Added more yesterday and early today. Betting that sp <$5 days are numbered.

0 · Reply

Buyorsell4321 Dec. 4 at 3:48 PM

$ABEO Short ratio 13+ days, over 33% short, and we keep drifting higher. Ladies and gentlemen, buckle up… this is not going to be an easy exit for the shorts. The air ahead doesn’t just look turbulent it looks like a vacuum straight to warp speed. 🚀

0 · Reply

TimeForBio Dec. 4 at 3:38 PM

$ABEO My biggest holding. Ridiculous market cap.

0 · Reply

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2025, 2:52 PM EST - 24 days ago

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Nov 12, 2025, 12:11 PM EST - 24 days ago

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 11:37 AM EST - 24 days ago

Here's Why Abeona Therapeutics Popped Higher Today

Nov 12, 2025, 7:30 AM EST - 24 days ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 4 weeks ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Oct 30, 2025, 10:45 AM EDT - 5 weeks ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Oct 20, 2025, 8:30 AM EDT - 6 weeks ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Oct 13, 2025, 7:30 AM EDT - 7 weeks ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 8, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Aug 29, 2025, 7:30 AM EDT - 3 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 19, 2025, 3:25 PM EDT - 3 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 4:36 PM EDT - 4 months ago

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Jul 29, 2025, 10:00 AM EDT - 4 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 5 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 5 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 5, 2025, 5:48 AM EDT - 6 months ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

May 30, 2025, 8:46 AM EDT - 6 months ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:37 AM EDT - 7 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 14, 2025, 8:07 AM EDT - 7 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 30, 2025, 4:41 PM EDT - 7 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 29, 2025, 6:06 AM EDT - 7 months ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 7 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 27, 2025, 8:30 AM EDT - 7 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Apr 21, 2025, 10:00 AM EDT - 8 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Apr 12, 2025, 11:39 AM EDT - 8 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Mar 20, 2025, 3:20 PM EDT - 9 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 4, 2025, 9:00 AM EST - 9 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Jan 24, 2025, 12:40 PM EST - 11 months ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 3, 2024, 8:09 AM EDT - 1 year ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 11, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

smacsJHI Dec. 6 at 11:57 PM

$ABEO Have they mentioned a plan for possible EU expansion of ROW?

1 · Reply

commoncentsinvestor Dec. 6 at 8:22 PM

0 · Reply

commoncentsinvestor Dec. 6 at 8:03 PM

0 · Reply

FitzCatalyst Dec. 5 at 12:47 PM

$ABEO

0 · Reply

Lttiller Dec. 4 at 9:00 PM

$ABEO next major news coming out soon?

3 · Reply

PPT_for_me Dec. 4 at 7:16 PM

$ABEO Imagine shorting a company creating a cure for children with a horribly gruesome skin disease... disgusting.

3 · Reply

Playfire Dec. 4 at 4:52 PM

$ABEO That's right, Abeona has an unbelievable short interest rate and is still rising, let the cap fly!

1 · Reply

acm20 Dec. 4 at 4:46 PM

$ABEO Added more yesterday and early today. Betting that sp <$5 days are numbered.

0 · Reply

Buyorsell4321 Dec. 4 at 3:48 PM

0 · Reply

TimeForBio Dec. 4 at 3:38 PM

$ABEO My biggest holding. Ridiculous market cap.

0 · Reply

TragicRain Dec. 4 at 3:07 PM

$ABEO - Continues to do the Happy Happy dance......

0 · Reply

commoncentsinvestor Dec. 4 at 3:06 PM

$ABEO Abeona Therapeutics Stifel 2025 Healthcare Conference summary Complete event summary combining all related documents: earnings call transcript, report, and slide presentation. https://quartr.com/companies/abeona-therapeutics-inc_4039

0 · Reply

FitzCatalyst Dec. 4 at 2:59 PM

$ABEO

0 · Reply

Buyorsell4321 Dec. 4 at 1:36 PM

$ABEO Creditgoo said $CAPR would tank and then it launched 300% . 😃 He’s so good at being wrong it’s honestly impressive. If he goes bearish on ABEO again, the stock should automatically spike out of respect for the pattern. 🤣

0 · Reply

HedgeAlerts Dec. 4 at 7:44 AM

Hedge Alert Live - Protect Your Portfolio Contract: $ABEO $4.00 Put · DEC 19, 2025 Exp Entry Price: $0.05 - $0.15 Exit Price Target: $0.10 Profit Margin: +105% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

JimiJoJeeter Dec. 3 at 9:16 PM

$ABEO Nice close

0 · Reply

commoncentsinvestor Dec. 3 at 5:37 PM

$ABEO Kate Imhoff 1d I'm excited to be presenting about the ZEVASKYN® FDA approval at the 2nd Annual Cell & Gene Therapy Regulatory Affairs Summit from December 2-4 in Washington D.C.! It will be great to interact with my peers on Regulatory Affairs in the cell & gene therapy space. https://www.linkedin.com/posts/kate-imhoff-12k9_im-excited-to-be-presenting-about-the-zevaskyn-activity-7401438128626216960-Mnv7

0 · Reply

kenny91655 Dec. 3 at 4:00 PM

$ABEO creditgoo just got hammered in CAPR, if he is legit, he just lost a ton of money

1 · Reply

Cautiousamphybian Dec. 3 at 3:43 PM

$ABEO

0 · Reply

Marcel20 Dec. 3 at 2:34 PM

$ABEO bullish!

0 · Reply

FitzCatalyst Dec. 3 at 2:27 PM

$ABEO

0 · Reply

Buyorsell4321 Dec. 3 at 12:08 PM

$ABEO The setup here is getting dangerous for the shorts. In my view, they’re already trapped. The longer price holds at these levels, the more pressure builds for a violent upside move. Retail ownership is deep, the short interest is elevated, and the short-ratio is now over 9 days! Haha not exactly an easy exit. When this unleashes, it won’t be a gentle drift higher. It has the makings of a “strap-in” move the kind that can triple in a matter of days, in my opinion. And that’s exactly why I’m long with $500K+ in the trade. 😃

3 · Reply

Market Cap	263.91M
Revenue (ttm)	0.00
Net Income (ttm)	-63.73M
EPS (ttm)	N/A
PE Ratio	4.31
Forward PE	3.76
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	646,300
Avg Vol	1,820,118
Day's Range	N/A - N/A
Shares Out	54.19M
Stochastic %K	60%
Beta	1.12
Analysts	Strong Sell
Price Target	$20.64